pharma
Novartis
NovaPharmaNews editorial coverage mentioning Novartis — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Basel, CH
- Programs
- 0
- Drugs
- 0
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Novartis — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Novartis — regulatory, clinical, and market analysis.
EC Approves Itvisma Gene Therapy for SMA 2+
Novartis remibrutinib wins Phase 3 in CSU: what it means
Novartis remibrutinib is an oral, highly selective BTK inhibitor with Phase 3 success in chronic spontaneous urticaria. This plan frames the catalyst for BD teams, investors, and analysts, including efficacy, safety, and next milestones.
Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria
Novartis remibrutinib has Phase 3 support in chronic spontaneous urticaria, with evidence of early symptom improvement and sustained efficacy through 52 weeks. This plan frames the result for BD teams, investors, and analysts, including regulatory context and what to watch next.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
BMS Expands in Texas While Novartis Faces Tenant Challenges
Bristol Myers Squibb is planning a new campus in Texas, while Novartis is facing eviction issues with a tenant in Slovenia. These developments could reshape the competitive landscape.
Takeda and Novartis Layoffs: Implications for Pharma Industry
Takeda announces a reduction of 4,500 jobs while Novartis lays off biomedical research staff. This article explores the implications for the pharma sector.
Novartis Strengthens Prostate Cancer Treatment with Pluvicto
Novartis has reported stronger PSA responses with its drug Pluvicto in earlier-stage prostate cancer, indicating promising developments in oncology. This news could reshape competitive dynamics in the market.